Skip to Content

Nektar Therapeutics

Securities Class Action

  • Date:
  • 5/5/2026
  • Company Name:
  • Nektar Therapeutics
  • Stock Symbol:
  • NKTR
  • Class Period:
  • FROM 2/26/2025 TO 12/15/2025
  • Status:
  • Filed
  • Filing Date:
  • 3/6/2026
  • Court:
  • U.S. District Court: Northern California

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ:NKTR) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Nektar securities between February 26, 2025 and December 15, 2025, both dates inclusive (the “Class Period”). Investors have until May 5, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
 
According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (2) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial's results; (3) accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

 

On December 16, 2025, Nektar issued a press release "announcing topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin, a first-in-class IL-2 pathway agonist and regulatory T-cell (Treg) proliferator." The press release disclosed that the trial failed to reach statistical significance, which Nektar attributed to the inclusion of four patients who should not have been eligible to participate.

 

On this news, Nektar's stock price fell $4.14 per share, or 7.77%, to close at $49.16 per share on December 16, 2025.
 
If you purchased or otherwise acquired Nektar shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Nektar Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: